Elicera Therapeutics AB (publ) (ELIC.ST)
SEK 1.71
(-0.29%)
SEK 1.71
(-0.29%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -17.09 Million SEK | 11.71% |
| 2022 | -19.36 Million SEK | -47.59% |
| 2021 | -13.11 Million SEK | -363.82% |
| 2020 | -2.82 Million SEK | -1356.14% |
| 2019 | -194.25 Thousand SEK | -5418.47% |
| 2018 | -3520.00 SEK | 3.83% |
| 2017 | -3660.00 SEK | 16.63% |
| 2016 | -4390.00 SEK | -100.8% |
| 2015 | 548.18 Thousand SEK | -6.04% |
| 2014 | 583.4 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -5.43 Million SEK | -3.64% |
| 2024 Q2 | -6.83 Million SEK | -7.51% |
| 2023 Q4 | -5.24 Million SEK | -1.81% |
| 2023 Q3 | -5.14 Million SEK | -15.3% |
| 2023 FY | -28.32 Million SEK | -46.29% |
| 2023 Q1 | -2.26 Million SEK | 42.66% |
| 2023 Q2 | -4.46 Million SEK | -97.11% |
| 2022 Q2 | -3.64 Million SEK | 23.19% |
| 2022 Q1 | -4.74 Million SEK | -121.31% |
| 2022 FY | -19.36 Million SEK | -47.59% |
| 2022 Q4 | -3.95 Million SEK | 43.77% |
| 2022 Q3 | -7.02 Million SEK | -92.98% |
| 2021 Q3 | -6.75 Million SEK | -271.34% |
| 2021 Q2 | -1.81 Million SEK | 24.36% |
| 2021 FY | -13.11 Million SEK | -363.82% |
| 2021 Q1 | -2.4 Million SEK | 7.39% |
| 2021 Q4 | -2.14 Million SEK | 68.28% |
| 2020 Q1 | -4900.00 SEK | 0.0% |
| 2020 FY | -2.82 Million SEK | -1356.14% |
| 2020 Q4 | -2.59 Million SEK | -1099.04% |
| 2020 Q3 | -216.55 Thousand SEK | -1948.72% |
| 2020 Q2 | -10.57 Thousand SEK | -115.71% |
| 2019 FY | -194.25 Thousand SEK | -5418.47% |
| 2018 FY | -3520.00 SEK | 3.83% |
| 2017 FY | -3660.00 SEK | 16.63% |
| 2016 FY | -4390.00 SEK | -100.8% |
| 2015 FY | 548.18 Thousand SEK | -6.04% |
| 2014 FY | 583.4 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 93.134% |
| Ziccum AB (publ) | -21.56 Million SEK | 20.704% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -4.239% |
| BioArctic AB (publ) | 252.64 Million SEK | 106.767% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -1923.228% |
| Mendus AB (publ) | -100.65 Million SEK | 83.014% |
| Genovis AB (publ.) | 54.22 Million SEK | 131.529% |
| Intervacc AB (publ) | -93.57 Million SEK | 81.731% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -10.213% |
| Active Biotech AB (publ) | -46.48 Million SEK | 63.221% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 194.932% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 69.15% |
| Aptahem AB (publ) | -10.1 Million SEK | -69.19% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 94.682% |
| Kancera AB (publ) | -65.04 Million SEK | 73.715% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 87.3% |
| Fluicell AB (publ) | -26.87 Million SEK | 36.395% |
| Saniona AB (publ) | -81.06 Million SEK | 78.91% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -38.196% |
| Biovica International AB (publ) | -126.07 Million SEK | 86.439% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 59.778% |
| AcouSort AB (publ) | -17.48 Million SEK | 2.234% |
| Xintela AB (publ) | -57.23 Million SEK | 70.131% |
| Abliva AB (publ) | -96.54 Million SEK | 82.292% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 94.736% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -387.768% |
| OncoZenge AB (publ) | -15.9 Million SEK | -7.51% |
| Amniotics AB (publ) | -29.07 Million SEK | 41.195% |
| 2cureX AB (publ) | -36.36 Million SEK | 52.984% |
| CombiGene AB (publ) | -36.3 Million SEK | 52.91% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -16.778% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 95.552% |
| Camurus AB (publ) | 532.35 Million SEK | 103.211% |
| Corline Biomedical AB | -1.78 Million SEK | -856.168% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 90.542% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 58.985% |
| I-Tech AB | 24.43 Million SEK | 169.966% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 97.832% |
| Cyxone AB (publ) | -21.66 Million SEK | 21.073% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 83.866% |
| Biosergen AB | -27.26 Million SEK | 37.296% |
| Cantargia AB (publ) | -290.01 Million SEK | 94.105% |
| NextCell Pharma AB | -43.17 Million SEK | 60.4% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 90.542% |
| Nanologica AB (publ) | -69.96 Million SEK | 75.564% |
| SynAct Pharma AB | -224.49 Million SEK | 92.385% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 61.3% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 28.63% |
| LIDDS AB (publ) | -40.67 Million SEK | 57.968% |
| Lipum AB (publ) | -37.25 Million SEK | 54.109% |
| BioInvent International AB (publ) | -369.94 Million SEK | 95.379% |
| Alzinova AB (publ) | -16.52 Million SEK | -3.476% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 93.254% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -167.411% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 85.143% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 15.109% |
| Simris Alg AB (publ) | -36.63 Million SEK | 53.333% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 88.336% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 94.493% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 84.586% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -47.815% |